Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody
HONG KONG - Chinese drug manufacturer and distributor Simcere Pharmaceutical Group filed an investigational new drug application earlier this month with China's State FDA to launch a Phase I trial of APX003, a novel humanized rabbit monoclonal antibody to treat solid-tumor cancer